The research tackles a stubborn gap in genetics. Genome-wide association studies have linked hundreds of DNA variants to obesity and cardiometabolic disease, but most of these variants sit in stretches of the genome that do not code for proteins. Interpreting them has been notoriously difficult, in part because the relevant regulatory effects often operate in specific cell types and often influence genes located far away on the genome, not just their immediate neighbors. Traditional bulk tissue studies, which average signals across many cell types, tend to wash out these cell-specific effects, leaving the biological story hidden in the noise.

To cut through that noise, the team turned to single nucleus RNA-sequencing of human subcutaneous adipose tissue biopsies. Rather than measuring average gene expression across a whole tissue sample, this technology profiles the transcriptomes of individual nuclei, allowing researchers to distinguish adipocytes from adipose stem and progenitor cells, immune cells and other residents of fat tissue. With this resolution, the investigators first asked a foundational question: how much of the inherited risk for cardiometabolic disease can be traced to regulatory activity around genes that mark specific fat-tissue cell types?

The answer was striking. The team found that the heritability of epigenetic sites surrounding adipocyte marker genes in subcutaneous adipose tissue was significantly enriched for abdominal obesity, the pattern of fat accumulation around the abdomen that carries the strongest cardiometabolic risk. These cell-type marker genes were also enriched for central pathways of adipocyte function, suggesting that the genes that define a fat cell as a fat cell are precisely the genes where obesity-related genetic risk concentrates. In other words, the genetic architecture of obesity appears to be written, in large part, into the core identity of the adipocyte itself.

With the cell-type landscape mapped, the researchers searched for transcription factors, the proteins that bind DNA and switch genes on or off, encoded within the functional pathways of the adipocyte marker genes. One name rose above the rest: SREBF1, which encodes sterol regulatory element-binding transcription factor 1, a long-recognized master regulator of fat synthesis and lipid metabolism. SREBF1 emerged as the most frequently represented transcription factor across these adipocyte pathways, making it a prime candidate for deeper genetic scrutiny.

That scrutiny centered on a variant called rs8079321, a DNA change already flagged by genome-wide association studies as associated with abdominal obesity and type 2 diabetes. The team showed that this variant regulates SREBF1 expression in cis, meaning it alters the activity of the SREBF1 gene itself, which sits nearby on the genome. Such cis effects are the bread and butter of expression quantitative trait locus studies, which link genetic variants to differences in gene expression. But the researchers went a crucial step further, asking whether a variant that dials SREBF1 up or down might also, through the transcription factor’s own activity, change the expression of the many genes SREBF1 controls, effects that would occur in trans, across the genome.

To test this, the investigators examined adipocyte-specific expression in single nucleus RNA-sequencing data and then verified their findings in an independent cohort of subcutaneous adipose tissue single nucleus RNA-sequencing samples. The result held up: the risk allele of rs8079321 affected adipocyte expression of SREBF1 in cis and, remarkably, the expression of 89 adipocyte marker genes in trans. Nearly one hundred genes, all markers of the fat cell’s core identity, shifted their expression depending on which version of this single variant a person carried. This is allele-specific trans regulation at scale, and it had been verified in human tissue rather than inferred from cell lines or animal models.

The final and arguably most consequential step connected these molecular effects to disease risk at the population level. Using data from the UK Biobank, a research resource containing genetic and health information from hundreds of thousands of participants, the team constructed partitioned polygenic risk scores for abdominal obesity and type 2 diabetes, focusing specifically on the 89 trans-regulated genes. They found that these partitioned risk scores differed depending on which allele of rs8079321 individuals carried. The implication is profound: the trans effects observed at the level of individual fat cell transcripts extend upward to shape polygenic risk for highly common cardiometabolic diseases.

This chain of evidence, from a single regulatory variant, through a master transcription factor, to a coordinated program of gene expression in a specific cell type, and finally to measurable differences in inherited disease risk, illustrates a mechanism that may underlie far more of the missing heritability of complex disease than previously appreciated. If variants like rs8079321 can exert allele-specific control over whole gene programs in key cell types, then many genome-wide association signals that currently point to anonymous stretches of DNA may in fact be pointing to cis-regulated transcription factors whose real impact lies in the trans programs they govern. The study’s authors suggest that integrating single-cell omics with biobank data, as they did here, offers a generalizable strategy for identifying such human trans-expression quantitative trait locus genes.

The work also carries practical weight for a world grappling with obesity. With global obesity prevalence high and mechanistic, cell-type-level knowledge of predisposing genes still limited, pinpointing SREBF1 as an allele-specific hub of adipocyte regulation gives researchers a concrete molecular node to study. It suggests that the path from genetic risk to metabolic disease may run through the transcriptional identity of the fat cell itself, and that interventions aimed at modulating SREBF1 activity, or the pathways it controls in adipocytes, could one day help blunt the impact of risk variants that millions of people carry. For now, the study stands as a technical tour de force and a template: by looking at disease genetics one cell type at a time, researchers are beginning to read the fine print of the human genome that bulk studies have long blurred over.

Subject of Research: Allele-specific trans regulation of adipocyte gene expression by SREBF1 and its relationship to cardiometabolic disease risk

Article Title: Integration of single cell omics with biobank data discovers allele-specific trans effects of SREBF1 on adipocyte expression of nearly 100 genes

Article References: Integration of single cell omics with biobank data discovers allele-specific trans effects of SREBF1 on adipocyte expression of nearly 100 genes. (n.d.). https://doi.org/10.1186/s13073-026-01790-z

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01790-z

Keywords: SREBF1, adipocytes, single nucleus RNA-sequencing, trans-eQTL, subcutaneous adipose tissue, abdominal obesity, type 2 diabetes, polygenic risk score, GWAS, transcription factors, gene regulation, UK Biobank

The study, led by Hye Ju Yeo and Ha Lim Kim of Pusan National University Yangsan Hospital in South Korea, together with colleagues including Woo Hyun Cho, examined 1,107 adults with sepsis who had undergone abdominal CT imaging as part of their clinical care. Rather than relying on height and weight, the team deployed an automated segmentation pipeline built on the nnU-Net framework, a self-configuring deep learning architecture that has become a standard tool for biomedical image analysis, supplemented by the TotalSegmentator software capable of delineating more than one hundred anatomic structures in a single scan. The algorithms measured the cross-sectional areas of subcutaneous adipose tissue, the fat layer beneath the skin, and visceral adipose tissue, the fat packed around internal organs, at the level of the third and fourth lumbar vertebrae, a standard landmark in body composition research.

The technical rationale for this approach is straightforward. Body mass index cannot distinguish between fat stored under the skin and fat stored deep within the abdomen, yet these two depots behave in profoundly different ways biologically. Subcutaneous adipose tissue acts largely as a passive energy reservoir and, in some contexts, appears metabolically protective, sequestering lipids away from the liver, muscle, and bloodstream. Visceral adipose tissue, by contrast, drains directly into the portal circulation, is richly innervated and hormonally active, and is strongly associated with insulin resistance, systemic inflammation, and adverse outcomes across a range of acute and chronic illnesses. The idea that these depots might carry opposite prognostic signals during sepsis is not new, but measuring them reliably has traditionally required painstaking manual tracing of CT images, which is impractical at scale.

Among the 1,107 patients in the cohort, 300, or 27.1 percent, died within 28 days of their sepsis diagnosis during the index hospitalization. When the researchers fed their imaging-derived measurements into Cox proportional hazards models adjusted for clinically selected covariates, a clear and internally consistent picture emerged. Greater subcutaneous adipose tissue area was associated with lower mortality, with an adjusted hazard ratio of 0.83 per one standard deviation increase, a statistically significant protective association. Obesity itself, defined here as a body mass index of 25 kilograms per square meter or higher in keeping with thresholds commonly used in Asian populations, was also associated with lower mortality, with an adjusted hazard ratio of 0.62. But the most telling variable was the ratio of visceral to subcutaneous fat: patients with a higher VAT/SAT ratio had significantly higher mortality, with an adjusted hazard ratio of 1.14 per standard deviation increase.

That pattern reframes the obesity paradox in mechanistic terms. It suggests that what has appeared to be a survival advantage of obesity in sepsis may actually reflect the composition of body fat rather than its total quantity. A patient whose excess weight is dominated by subcutaneous fat may be metabolically better buffered against the catabolic storm of critical illness than a leaner patient whose fat is disproportionately visceral. The finding aligns with a growing body of work. A 2016 study in Critical Care Medicine by Pisitsak and colleagues found that an increased visceral-to-subcutaneous adipose tissue ratio in septic patients was associated with adverse outcomes, and subsequent research suggested that the survival benefit of a low ratio depends on the balance of LDL cholesterol clearance versus production during infection. Population-level analyses in the UK Biobank have similarly shown that abdominal fat distribution outperforms traditional anthropometric indices in predicting sepsis outcomes.

The stratified analyses added further texture, though with appropriate statistical caution. In exploratory models stratified by body mass index category, the protective association of subcutaneous fat was most pronounced among underweight patients, where greater subcutaneous adipose tissue area carried an adjusted hazard ratio of 0.37, meaning a substantially lower hazard of death. Conversely, among patients with obesity, a higher visceral-to-subcutaneous ratio was associated with a markedly elevated mortality risk, with an adjusted hazard ratio of 1.48. In other words, not all obesity is created equal: a patient with obesity whose fat is predominantly subcutaneous may carry a very different prognosis from one whose obesity is visceral-dominant. The authors were careful to note, however, that formal interaction tests between these imaging measures and body mass index category did not reach statistical significance, with P values of 0.145 and 0.127, meaning the apparent effect modification could reflect chance and requires confirmation in larger, independent cohorts.

The study also interrogated skeletal muscle, a dimension of body composition that has gained increasing attention in critical care. Sarcopenia, the loss of muscle mass and function, is common in critically ill patients and has been linked to worse long-term outcomes, partly because sepsis itself induces profound muscle wasting through disrupted autophagy and mitochondrial dysfunction. The team quantified psoas muscle measures at the same lumbar level, including the psoas muscle index, a conventional marker of muscle quantity. Strikingly, muscle size itself did not retain an independent association with mortality after adjustment. What did survive the statistical scrutiny was muscle quality: a higher proportion of low-attenuation muscle, which reflects fatty infiltration of the muscle and is a radiographic signature of myosteatosis, was associated with higher mortality, with an adjusted hazard ratio of 1.14. A joint phenotype combining a high visceral-to-subcutaneous ratio with a low psoas muscle index, which the investigators had hypothesized might identify particularly high-risk patients, was not significant after adjustment.

These findings carry real implications for how risk is characterized in the intensive care unit. Abdominal CT scans are already obtained routinely in many sepsis patients to search for the infectious source, meaning the raw imaging data needed for automated body composition analysis often exists before anyone thinks to use it prognostically. A pretrained deep learning pipeline can extract these measurements in seconds without manual labor, and the underlying software is publicly available, making the approach reproducible and potentially deployable as a clinical decision-support tool. If validated externally, a VAT/SAT ratio or a low-attenuation muscle fraction could complement, and in some cases correct, the crude signal provided by body mass index, helping clinicians identify high-risk patients who would be missed by conventional anthropometry, including visceral-dominant patients with obesity and sarcopenic patients of normal weight.

The authors and independent commentators are quick to emphasize the study’s limitations. It was a single-center, retrospective cohort, which raises the possibility of selection bias, since only patients who happened to receive abdominal CT imaging could be included. The subgroup findings, however compelling, rest on exploratory analyses with non-significant interaction tests, and the skeletal muscle results in particular require external validation before they can inform practice. Residual confounding by illness severity, nutritional status, and chronic disease cannot be excluded in any observational design. Still, the convergence of this work with prior mechanistic and epidemiological evidence, and the elegance of using artificial intelligence to turn diagnostic scans that already exist into prognostic information that costs nothing extra, marks a meaningful step forward. The obesity paradox in sepsis has long been an embarrassment to simple models of body size and disease; deep learning analysis of where the body stores its fat may finally explain what the scale never could.

Subject of Research: Deep learning–based CT analysis of abdominal fat distribution and its association with 28-day mortality in sepsis patients

Article Title: Deep learning–derived abdominal adiposity phenotypes and 28-day mortality in sepsis

Article References: Yeo, H. J., Kim, H. L., Kim, K., Jang, J. H., Choi, E., Seol, H. Y., Lee, S. E., & Cho, W. H. (2026). Deep learning–derived abdominal adiposity phenotypes and 28-day mortality in sepsis. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02220-1

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02220-1

Keywords: sepsis, obesity paradox, visceral adipose tissue, subcutaneous adipose tissue, deep learning, nnU-Net, body composition, computed tomography, 28-day mortality, psoas muscle, myosteatosis, critical care